|
1
|
Chen Q and Yang XF: Research progress in
targeted therapy of hepatocellular carcinoma. Chin Med Sci J.
36:57–65. 2021.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Wang T, Zhang Q, Wang N, Liu Z, Zhang B
and Zhao Y: Research progresses of targeted therapy and
immunotherapy for hepatocellular carcinoma. Curr Med Chem.
28:3107–3146. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hatanaka T, Naganuma A and Kakizaki S:
Lenvatinib for hepatocellular carcinoma: A literature review.
Pharmaceuticals (Basel). 14(36)2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shen YC, Lin ZZ, Hsu CH, Hsu C, Shao YY
and Cheng AL: Clinical trials in hepatocellular carcinoma: An
update. Liver Cancer. 2:345–364. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Davies F and Baz R: Lenalidomide mode of
action: Linking bench and clinical findings. Blood Rev. 24 (Suppl
1):S13–S19. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yokouchi H, Nagasato D, Mitamura Y, Egawa
M, Tabuchi H, Misawa S, Kuwabara S and Baba T: Alterations in
choroidal vascular structures due to serum levels of vascular
endothelial growth factor in patients with POEMS syndrome. Sci Rep.
13(10650)2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Motz GT and Coukos G: The parallel lives
of angiogenesis and immunosuppression: Cancer and other tales. Nat
Rev Immunol. 11:702–711. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA,
Lieftink C, Wang L, Wang S, Wang C, Dias MH, et al: EGFR activation
limits the response of liver cancer to lenvatinib. Nature.
595:730–734. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ou DL, Chang CJ, Jeng YM, Lin YJ, Lin ZZ,
Gandhi AK, Liao SC, Huang ZM, Hsu C and Cheng AL: Potential
synergistic anti-tumor activity between lenalidomide and sorafenib
in hepatocellular carcinoma. J Gastroenterol Hepatol. 29:2021–2031.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Shahda S, Loehrer PJ, Clark RS, Spittler
AJ, Althouse SK and Chiorean EG: Phase I study of lenalidomide and
sorafenib in patients with advanced hepatocellular carcinoma.
Oncologist. 21:664–665. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Qin Y, Han S, Yu Y, Qi D, Ran M, Yang M,
Liu Y and Li Y, Lu L, Liu Y and Li Y: Lenvatinib in hepatocellular
carcinoma: Resistance mechanisms and strategies for improved
efficacy. Liver Int: May 3, 2024 (Epub ahead of print).
|
|
13
|
Tsoris A and Marlar CA: Use of the child
pugh score in liver disease. In: StatPearls [Internet]. Treasure
Island (FL): StatPearls Publishing, 2024.
|
|
14
|
Gmür A, Kolly P, Knöpfli M and Dufour JF:
FACT-Hep increases the accuracy of survival prediction in HCC
patients when added to ECOG Performance Status. Liver Int.
38:1468–1474. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Moazzam Z, Alaimo L, Endo Y, Lima HA,
Shaikh CF, Ratti F, Marques HP, Cauchy F, Lam V, Poultsides GA, et
al: Variations in textbook oncologic outcomes after curative-intent
resection: Early versus intermediate hepatocellular carcinoma based
on Barcelona clinic liver cancer criteria and child-pugh
classification. Ann Surg Oncol. 30:750–759. 2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhong BY, Jiang JQ, Sun JH, Huang JT, Wang
WD, Wang Q, Ding WB, Zhu XL and Ni CF: Prognostic performance of
the china liver cancer staging system in hepatocellular carcinoma
following transarterial chemoembolization. J Clin Transl Hepatol.
11:1321–1328. 2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang Y, Yuan D, Sun H, Pan X, Lu F, Li H,
Huang Y and Tang S: Non-invasive preoperative prediction of
Edmondson-Steiner grade of hepatocellular carcinoma based on
contrast-enhanced ultrasound using ensemble learning. Front Oncol.
13(1116129)2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Koulouris A, Tsagkaris C, Spyrou V, Pappa
E, Troullinou A and Nikolaou M: Hepatocellular carcinoma: An
overview of the changing landscape of treatment options. J
Hepatocell Carcinoma. 8:387–401. 2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
National Health Commission of the People's
Republic of China Medical Administration and Hospital
Administration. Standardization for diagnosis and treatment of
hepatocellular carcinoma (2022 edition). Chin J Dig Surg.
21:143–168. 2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Safran H, Charpentier K, Dubel G, Soares
G, Berz D, Shipley JL, Faricy-Anderson KE, Plette AM, Bishop K and
Espat NJ: Lenalidomide for advanced hepatocellular cancer (HCC) in
patients progressing on or intolerant to sorafenib. J Clin Oncol.
28 (15 Suppl)(S4159)2010.
|
|
21
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cheng AL, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron AD, Park JW, Han G, Jassem J, et al: Phase III
trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line
treatment of patients (pts) with unresectable hepatocellular
carcinoma (uHCC). J Clin Oncol. 35 (15 Suppl)(S4001)2017.
|
